Danske Bank predicts Novo Nordisk will lead USD 100bn obesity market
In an analyst note, Danske Bank predicts that Novo Nordisk and Eli Lilly will snap up the biggest shares of the obesity treatment market, even though lots of companies are ready to pounce.
by marketwire, translated by catherine brett
The global market for obesity treatments is growing dramatically, and so far, Novo Nordisk is leading the race, though several competitors have also thrown their hats into the ring, a Danske Bank analyst note concludes.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo reaches share milestone, analyst credits Wegovy
For subscribers
Bank counts on double-digit growth for Novo Nordisk in 2023
For subscribers
